Construction of Neutropenic P. Aeruginosa Infection Model

In today's world, superbug infections are a growing concern for public health, particularly for immunocompromised patients. Among these bacterial infections, Pseudomonas aeruginosa is a notorious pathogen that can cause life-threatening infections in immunocompromised individuals. Ace Therapeutics recognizes the need to develop effective treatments against superbugs such as P. aeruginosa.

Therefore, we provide development services to construct state-of-the-art neutropenic P. aeruginosa infection models to help our clients test their anti-infective agents.

Introduction to Neutropenic P. Aeruginosa Infection Model

The neutropenic P. aeruginosa infection model is a preclinical animal model that is commonly used to study infections caused by the bacterial pathogen. This model is widely used in the development of new antibiotics, vaccines, and other anti-infective agents.

This model has several advantages over other animal models of P. aeruginosa infection. Neutropenic animals are more susceptible to infection, which allows for the detection of smaller changes in bacterial burden and more sensitive measurements of bacterial clearance. And the model allows for the evaluation of new anti-superbug agents.

Development Services We Offer

At Ace Therapeutics, we provide a range of services to support the development of P. aeruginosa infection models.

  • Our services include innovative and robust animal model design and implementation. Our model services are centered around the neutropenic P. aeruginosa infection model. if you are looking for an animal study design and implementation methodology that is truly at the forefront of scientific innovation, then look no further than our organization.
  • Our services also include in vitro assessments. By combining our in vitro services with our animal research services, our clients are able to conduct a comprehensive and thorough evaluation of potential therapies. This can provide useful insights into your drug development and optimization.

Construction Process

  • Inducing neutropenia in the animal model
  • Intranasal infection with P. aeruginosa
  • Adjusting the bacterial load and the duration of the infection
  • The evaluation of both the efficacy and safety of anti-infective agents

Common Applications

The neutropenic P. aeruginosa infection model is an important research tool that can be used in the development of drugs for P. aeruginosa infection.

  • Our model construction services offer an extensive array of possibilities for conducting rigorous evaluations of the efficacy of a broad range of candidates or drugs against the P. aeruginosa. Whether your research endeavors encompass the investigation of innovative phage therapy, cutting-edge antibiotics, revolutionary vaccines, or any other relevant area of study, our model construction services will provide you with a powerful and versatile platform for conducting comprehensive assessments.
  • Our model construction services are also uniquely suited to exploring and analyzing the complex mechanisms of P. aeruginosa infection and drug resistance. The detailed models we construct can provide valuable insights into the mechanisms of the P. aeruginosa infection process your project studies, and can even help identify potential drug targets.

Our team of experts is dedicated to providing customized solutions to our clients and delivering high-quality results. Contact us today to learn more about our services and how we can help you in your drug development efforts.


  1. Stainton S M, et al. Efficacy of humanized cefiderocol exposures over 72 hours against a diverse group of Gram-negative isolates in the neutropenic murine thigh infection model. Antimicrobial agents and chemotherapy, 2019, 63(2): e01040-18.
  2. Wood S J, et al. Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics. Cells, 2023, 12(1): 199.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Get in touch with our team immediately.